Celtic Renewables Produces 500 Tons of Biosolvents; Pharma Demand dwarfs Supply

Celtic Renewables produces roughly 500 tons of biosolvent per year — about 100 tons of bioacetone and 400 tons of biobutanol — a volume its chief commercial officer calls a drop in the ocean of the global solvent market. The company's first commercial plant will lift capacity to 10,000 tons, and even that output, according to Bettina Brierley, would likely satisfy a single requirement of one large pharmaceutical company.

The UK biotechnology firm won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. PharmTech interviewed Brierley, who has spent more than 35 years in the chemical industry in senior roles at Hoechst AG, Clariant AG and Caldic UK, about adoption, capacity, pricing and supply security for the company's biosolvents.

The company's patented biorefining process converts low-value waste streams into chemicals the pharmaceutical industry can use.

Why adoption is straightforward

Adoption, Brierley explains, is relatively simple because the company's bioacetone and biobutanol function as drop-in replacements for their fossil-derived equivalents. Customers therefore avoid an additional regulatory clearance step. "As long as the solvents meet pharmaceutical specifications, replacement is uncomplicated," she says.

Pharmaceutical buyers impose one requirement: a third-party verified life cycle analysis, delivered in a specific format known as PACT, which the industry uses to upload the data into its own systems.

For R&D managers weighing portfolio shifts, the implication is direct: swapping biosolvents into existing workflows carries no requalification burden beyond standard specification checks, provided the LCA documentation arrives in PACT format.

What does 10,000 tons actually buy?

The arithmetic of supply is sobering. Current annual output of 500 tons covers a fraction of one large buyer's needs. The first commercial plant, at 10,000 tons per year, would close only part of that gap. Celtic Renewables wants to operate 10 such plants eventually, though Brierley acknowledges that ambition will take time.

That timeline matters for procurement teams. Any sourcing strategy built on these solvents must assume constrained volumes for years, with allocation likely favoring early, committed customers.

Feedstock supply is less of a constraint. The next commercial plant would consume roughly 5% of Scotland's available potato waste alone, and Brierley describes feedstocks as abundant.

How realistic is the price?

Pricing has moved toward realism, according to Brierley. Early expectations of a steep premium reflected the high cost of manufacturing in a demonstrator plant. The company has since built a cost model around the first commercial plant and now prices on that basis.

This marks a shift from demonstration-stage economics to commercial-plant economics — the difference between paying for a pilot facility's overhead and paying for a plant designed for volume. Buyers evaluating quotes today can treat the demonstrator-era premium as outdated.

Can pharma rely on the supply?

On supply security, Brierley confirms customers will not be single sourced. Once the commercial plant is running, the demonstrator plant remains in operation, serving both as a backup and as a testbed for new feedstocks.

That dual-plant arrangement gives buyers a redundancy option unusual for a supplier at this scale, though total redundancy across both facilities remains well below the 10-plant target.

The road ahead

The trajectory Celtic Renewables outlines — from 500 tons to 10,000 tons to a hoped-for 100,000 tons across 10 plants — depends on successive construction cycles the company has not yet dated. For now, pharmaceutical manufacturers can qualify drop-in biosolvents with verified PACT-format LCAs, buy realistic commercial-plant pricing, and plan around volumes that one large customer could absorb alone.